Navigation Links
Isis Pharmaceuticals Files Patent Infringement Suit Against Santaris Pharma
Date:9/23/2011

CARLSBAD, Calif., Sept. 23, 2011 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today it has filed a patent infringement lawsuit against Santaris Pharma A/S and Santaris Pharma A/S Corp. in the United States District Court of the Southern District of California.  Isis' infringement suit against Santaris is based upon Santaris' activities providing antisense drugs and antisense drug discovery services to several pharmaceutical companies.  As alleged in the complaint, these activities are not protected under the exemption from patent infringement for drug development.

Isis is the leading antisense company.  Through its commitment to innovation in antisense technology, Isis has generated a large patent estate that provides the Company with extensive protection for its drugs and technology.  Isis is the owner or exclusive licensee of approximately 1,550 issued patents worldwide that cover all facets of antisense drugs.  One portion of Isis' patent estate includes patents covering basic oligonucleotide chemical modifications, drug designs that optimize therapeutic properties of antisense drugs, and the use of antisense compounds in drug discovery.  In the filed complaint, Isis alleges infringement of U.S. Patent No. 6,326,199, entitled "Gapped 2' Modified Oligonucleotides" and U.S. Patent No. 6,066,500, entitled "Antisense Modulation of Beta Catenin Expression" as the basis of its action.

"Since Isis' inception, our commitment has been to create a platform technology that has the power to change drug discovery and the treatment of disease.  We have actively protected our inventions resulting in a substantial patent estate.  A key element of our business is to make our patented technology available to researchers and drug developers who want to work in the antisense field. This strategy has resulted in a broad cons
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... YORK , 21. Mai 2015 ... DPRX ), ein Unternehmen für ... auf die Entwicklung und Vermarktung von ... konzentriert, kündigte heute eine wissenschaftliche Posterpräsentation ... Phase-III-Zulassungsstudie des Unternehmens vorstellt, OneStep-1 und ...
(Date:5/21/2015)... CHICAGO , May 21, 2015  Heidrick & ... executive search , leadership consulting and ... life sciences expertise among global practices announcing the addition ... Chicago office. Dietlin ... has worked globally and across R&D, Medical and Commercial ...
(Date:5/21/2015)... , May 21, 2015  Today, eight ... who prescribe biologics – Alliance for Patient ... College of Rheumatology, Biologics Prescribers Collaborative, Clinical ... Endocrine Society, and North American Society for ... a letter to U.S. Food and Drug ...
Breaking Medicine Technology:Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 2Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 3Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 4Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 5Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 6Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 7Heidrick Increases Healthcare and Life Sciences Expertise 2Physician Groups Urge FDA to Ensure Patient Safety With Greater Transparency in Biosimilar Labeling 2Physician Groups Urge FDA to Ensure Patient Safety With Greater Transparency in Biosimilar Labeling 3Physician Groups Urge FDA to Ensure Patient Safety With Greater Transparency in Biosimilar Labeling 4
... Jan. 14, 2011 New clinical research data suggests ... tools used by physicians and provide accurate identification of ... neurodegeneration linked to Alzheimer,s Disease (AD).  Flutemetamol, a GE ... phase III development, is being studied to identify the ...
... Baylor Health Care System is today announcing its intent ... in North Texas through the implementation of the electronic ... is one of thousands of hospitals and eligible professionals ... of Health and Human Services (HHS) to demonstrate its ...
Cached Medicine Technology:GE Healthcare Presents Flutemetamol Data for Detection of Amyloid Plaque Linked to Alzheimer's Disease 2GE Healthcare Presents Flutemetamol Data for Detection of Amyloid Plaque Linked to Alzheimer's Disease 3Baylor Health Care System Registers its Commitment to Achieve Meaningful Use of the Electronic Health Record 2
(Date:5/22/2015)... Wimbledon Health Partners, the leading on-site ... and NCV testing , is proud to announce ... American National athlete, to the Wimbledon Athletics division. ... level of testing and information it provides to be ... trainers, this way they can focus on the task ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 Steven Winter ... Marc Zuluaga, has been selected by Consulting-Specifying Engineer (CSE) ... award winners are featured in the May/June issue of ... building industry professionals age 40 and younger who have, ... community, as well as in other areas of their ...
(Date:5/22/2015)... Calif. (PRWEB) May 22, 2015 Bryce ... opened Anaheim Fit Body Boot Camp, recently accepted his ... so quickly after the launch of his location evidences ... the Anaheim community. , Fit Body Boot Camp is ... boot camp franchise with hundreds of locations across North ...
(Date:5/22/2015)... May 22, 2015 Javon Bea ... be recognized for providing the highest quality emergency care ... health care decision-making,” said Javon R. Bea, President and ... commitment of our employee/partners to care for and respond ... Hospitals do not apply for this award, but are ...
(Date:5/21/2015)... Los Angeles, California (PRWEB) May 21, 2015 ... Angeles area at the Hilton Hotel in San Gabriel on ... heard over and over again from men and women who ... can find the right partner." , "Many singles think that ... right person. The seeker would go from one relationship to ...
Breaking Medicine News(10 mins):Health News:Wimbledon Athletics Recruits Team USA Athlete 2Health News:Wimbledon Athletics Recruits Team USA Athlete 3Health News:Steven Winter Associates’ Marc Zuluaga Earns Innovative Engineering Award 2Health News:Healthy Living Brought to Anaheim— New Fitness Boot Camp Acquires 100 Clients 2Health News:Mercy Hospital and Trauma Center Receives Women’s Choice Award for Emergency Care - Mercy Health System Javon Bea 2Health News:Bestselling Author Sheds Light on Why Modern Dating is Hurting People's Chances of Finding a Lasting Relationship 2
... doesn,t prove it,s safe, critics say , , TUESDAY, April ... appears to slow the progression of atherosclerosis in diabetic ... them from new cardiac problems, according to the results ... been associated with increased risk of heart attack and ...
... reduction in Meth use, PALTO ALTO, Calif., ... its new advertising campaign, including a series of,television ... the Oscar-nominated director and producer whose works,include "Babel," ... launched,today in Montana, are designed to communicate the ...
... his April 1, 2008 show,Dr. Phil finally brought MRSA ... aureus) has been relatively unseen on,national TV. Dr. Phil ... an entire show to the problem. The program showcased ... had a son die as a result,of the deadly ...
... Ga., April 1, 2008 Immucor, Inc.,(Nasdaq: ... instrument-reagent,systems to the blood transfusion industry, today reported ... 29, 2008., Revenue for the fiscal third ... in the same period last year. Of the ...
... sixfold increase in positive portrayal of substance abuse over ... -- Rap music is glamorizing drug use, according to ... Berkeley, who found a sixfold increase in drug ... "Positive portrayals of drug use have increased over time, ...
... Fashion, Kid Sister, Emmanuel Jal & More Help Mobilize College Students ... ... mtvU ( http://www.mtvu.com/ ),MTV,s Emmy-winning college network, in partnership with ... a month of exclusive album leaks and video premieres on mtvU.com,and ...
Cached Medicine News:Health News:Avandia May Slow Atherosclerosis After Bypass Surgery 2Health News:Avandia May Slow Atherosclerosis After Bypass Surgery 3Health News:Oscar-Nominated Filmmaker Alejandro Gonzalez Inarritu Directs New Meth Project Advertising Campaign 2Health News:Oscar-Nominated Filmmaker Alejandro Gonzalez Inarritu Directs New Meth Project Advertising Campaign 3Health News:Oscar-Nominated Filmmaker Alejandro Gonzalez Inarritu Directs New Meth Project Advertising Campaign 4Health News:Daytime TV Addresses the Onslaught of MRSA Cases in U.S. 2Health News:Immucor Announces Record Fiscal Third Quarter Results 2Health News:Immucor Announces Record Fiscal Third Quarter Results 3Health News:Immucor Announces Record Fiscal Third Quarter Results 4Health News:Immucor Announces Record Fiscal Third Quarter Results 5Health News:Immucor Announces Record Fiscal Third Quarter Results 6Health News:Immucor Announces Record Fiscal Third Quarter Results 7Health News:Immucor Announces Record Fiscal Third Quarter Results 8Health News:Rap Music Glorifying Drug Use 2Health News:mtvU Unleashes Month OF Exclusive Album 'Leaks' & Music Video Premieres in Continued Fight Against Darfur Genocide 2Health News:mtvU Unleashes Month OF Exclusive Album 'Leaks' & Music Video Premieres in Continued Fight Against Darfur Genocide 3Health News:mtvU Unleashes Month OF Exclusive Album 'Leaks' & Music Video Premieres in Continued Fight Against Darfur Genocide 4Health News:mtvU Unleashes Month OF Exclusive Album 'Leaks' & Music Video Premieres in Continued Fight Against Darfur Genocide 5
... a compact Latex based reagent kit to detect ... to determine the level of RF semi-quantitatively in ... The kit includes antigen coated fine latex particles ... in plastic squeezable dropping bottles, re-usable plastic slide, ...
RFScan Latex Test Kit-100...
The Array 360 CEAL streamlines processes with computer enhancements and optimizes productivity by offering an exclusive design for aliquot samples....
ELISA kit for detection of Rheumatoid Factor....
Medicine Products: